BR112022003790A2 - Método para selecionar um peptídeo neoantigênico tumoral, peptídeos neoantigênicos tumorais, peptídeo neoantigênico tumoral isolado, população de células dendríticas autólogas, vacina ou composição imunogênica, anticorpos, método de produção de um anticorpo, receptor de células t, polinucleotídeo, vetor, célula imune, célula t, peptídeo neoantigênico e população de células imunes - Google Patents
Método para selecionar um peptídeo neoantigênico tumoral, peptídeos neoantigênicos tumorais, peptídeo neoantigênico tumoral isolado, população de células dendríticas autólogas, vacina ou composição imunogênica, anticorpos, método de produção de um anticorpo, receptor de células t, polinucleotídeo, vetor, célula imune, célula t, peptídeo neoantigênico e população de células imunesInfo
- Publication number
- BR112022003790A2 BR112022003790A2 BR112022003790A BR112022003790A BR112022003790A2 BR 112022003790 A2 BR112022003790 A2 BR 112022003790A2 BR 112022003790 A BR112022003790 A BR 112022003790A BR 112022003790 A BR112022003790 A BR 112022003790A BR 112022003790 A2 BR112022003790 A2 BR 112022003790A2
- Authority
- BR
- Brazil
- Prior art keywords
- neoantigenic peptide
- cell
- tumor neoantigenic
- tumor
- population
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 12
- 206010028980 Neoplasm Diseases 0.000 title abstract 11
- 238000000034 method Methods 0.000 title abstract 7
- 210000002865 immune cell Anatomy 0.000 title abstract 5
- 210000004027 cell Anatomy 0.000 title abstract 3
- 230000002163 immunogen Effects 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 108091008874 T cell receptors Proteins 0.000 title abstract 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 2
- 210000004443 dendritic cell Anatomy 0.000 title abstract 2
- 108091033319 polynucleotide Proteins 0.000 title abstract 2
- 102000040430 polynucleotide Human genes 0.000 title abstract 2
- 239000002157 polynucleotide Substances 0.000 title abstract 2
- 230000004927 fusion Effects 0.000 abstract 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 abstract 1
- 108700026244 Open Reading Frames Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464401—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/86—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Abstract
método para selecionar um peptídeo neoantigênico tumoral, peptídeos neoantigênicos tumorais, peptídeo neoantigênico tumoral isolado, população de células dendríticas autólogas, vacina ou composição imunogênica, anticorpos, método de produção de um anticorpo, receptor de células t, polinucleotídeo, vetor, célula imune, célula t, peptídeo neoantigênico e população de células imunes. a presente divulgação refere-se a um método para selecionar um peptídeo neoantigênico tumoral em que o referido método compreende: - uma etapa de identificação, entre sequências de mrna de células cancerosas de um sujeito, de uma sequência de transcrito de fusão compreendendo uma sequência de elemento transponível (te) e uma sequência exônica, e incluindo um quadro de leitura aberta (orf), e - uma etapa de seleção de um peptídeo neoantigênico tumoral de pelo menos 8 aminoácidos, codificado por uma parte do referido orf da sequência de transcritos de fusão, em que o referido orf se sobrepõe à junção entre o te e a sequência exônica, é te puro e/ou é não canônico, e em que o referido peptídeo neoantigênico tumoral se liga a pelo menos uma molécula do complexo principal de histocompatibilidade (mhc) do referido sujeito. a presente divulgação também se refere ao peptídeo neoantigênico tumoral obtido de acordo com o presente método, vacina ou composição imunogênica, anticorpos e células imunes derivadas destes e seu uso na terapia de câncer.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19306064 | 2019-09-02 | ||
| EP19218556 | 2019-12-20 | ||
| EP20305743 | 2020-07-01 | ||
| PCT/EP2020/074429 WO2021043804A1 (en) | 2019-09-02 | 2020-09-02 | Immunotherapy targeting tumor neoantigenic peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022003790A2 true BR112022003790A2 (pt) | 2022-05-31 |
Family
ID=72473518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022003790A BR112022003790A2 (pt) | 2019-09-02 | 2020-09-02 | Método para selecionar um peptídeo neoantigênico tumoral, peptídeos neoantigênicos tumorais, peptídeo neoantigênico tumoral isolado, população de células dendríticas autólogas, vacina ou composição imunogênica, anticorpos, método de produção de um anticorpo, receptor de células t, polinucleotídeo, vetor, célula imune, célula t, peptídeo neoantigênico e população de células imunes |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240082372A1 (pt) |
| EP (1) | EP4025244A1 (pt) |
| JP (1) | JP2022546524A (pt) |
| CN (1) | CN114746109A (pt) |
| AU (1) | AU2020343407A1 (pt) |
| BR (1) | BR112022003790A2 (pt) |
| CA (1) | CA3158775A1 (pt) |
| IL (1) | IL291040A (pt) |
| MX (1) | MX2022002578A (pt) |
| WO (1) | WO2021043804A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022233019A1 (en) * | 2021-03-11 | 2023-09-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tumor neoantigenic peptides |
| WO2023126458A1 (en) | 2021-12-28 | 2023-07-06 | Mnemo Therapeutics | Immune cells with inactivated suv39h1 and modified tcr |
| WO2023139269A1 (en) | 2022-01-21 | 2023-07-27 | Mnemo Therapeutics | Modulation of suv39h1 expression by rnas |
| EP4279085A1 (en) | 2022-05-20 | 2023-11-22 | Mnemo Therapeutics | Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease |
| WO2024062138A1 (en) | 2022-09-23 | 2024-03-28 | Mnemo Therapeutics | Immune cells comprising a modified suv39h1 gene |
| CN116836231B (zh) * | 2023-06-30 | 2024-02-13 | 深圳大学总医院 | 一种t(8;21)AML的新抗原肽及其应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| WO1991006309A1 (en) | 1989-11-03 | 1991-05-16 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
| CA2134773A1 (en) | 1992-06-04 | 1993-12-09 | Robert J. Debs | Methods and compositions for in vivo gene therapy |
| US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
| WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| JP2002524081A (ja) | 1998-09-04 | 2002-08-06 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 前立腺−特異的膜抗原に特異的な融合受容体およびその使用 |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| EP1287357A2 (en) | 2000-06-02 | 2003-03-05 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| WO2002077029A2 (en) | 2000-11-07 | 2002-10-03 | City Of Hope | Cd19-specific redirected immune cells |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| AU2008233051B2 (en) | 2007-03-30 | 2014-04-10 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| SG10201510092QA (en) | 2010-12-09 | 2016-01-28 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| CN110200997A (zh) | 2011-03-23 | 2019-09-06 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| CN107880101B (zh) | 2011-11-11 | 2021-12-21 | 弗雷德哈钦森癌症研究中心 | 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法 |
| EP3594245A1 (en) | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| SG10201609210SA (en) | 2012-05-03 | 2016-12-29 | Hutchinson Fred Cancer Res | Enhanced affinity t cell receptors and methods for making the same |
| WO2014031687A1 (en) | 2012-08-20 | 2014-02-27 | Jensen, Michael | Method and compositions for cellular immunotherapy |
| SG11201502598SA (en) | 2012-10-02 | 2015-05-28 | Sloan Kettering Inst Cancer | Compositions and methods for immunotherapy |
| JP6401704B2 (ja) | 2012-10-10 | 2018-10-10 | サンガモ セラピューティクス， インコーポレイテッド | Ｔ細胞を修飾する化合物およびその使用 |
| CA2988388C (en) * | 2015-04-23 | 2022-11-22 | Nantomics, Llc | Cancer neoepitopes |
| GB201511546D0 (en) * | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
-
2020
- 2020-09-02 WO PCT/EP2020/074429 patent/WO2021043804A1/en unknown
- 2020-09-02 EP EP20771475.9A patent/EP4025244A1/en active Pending
- 2020-09-02 CN CN202080077141.7A patent/CN114746109A/zh active Pending
- 2020-09-02 CA CA3158775A patent/CA3158775A1/en active Pending
- 2020-09-02 AU AU2020343407A patent/AU2020343407A1/en active Pending
- 2020-09-02 BR BR112022003790A patent/BR112022003790A2/pt unknown
- 2020-09-02 MX MX2022002578A patent/MX2022002578A/es unknown
- 2020-09-02 US US17/639,568 patent/US20240082372A1/en active Pending
- 2020-09-02 JP JP2022513957A patent/JP2022546524A/ja active Pending
-
2022
- 2022-03-01 IL IL291040A patent/IL291040A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3158775A1 (en) | 2021-03-11 |
| EP4025244A1 (en) | 2022-07-13 |
| US20240082372A1 (en) | 2024-03-14 |
| IL291040A (en) | 2022-05-01 |
| AU2020343407A1 (en) | 2022-03-24 |
| MX2022002578A (es) | 2022-06-02 |
| WO2021043804A1 (en) | 2021-03-11 |
| CN114746109A (zh) | 2022-07-12 |
| JP2022546524A (ja) | 2022-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022003790A2 (pt) | Método para selecionar um peptídeo neoantigênico tumoral, peptídeos neoantigênicos tumorais, peptídeo neoantigênico tumoral isolado, população de células dendríticas autólogas, vacina ou composição imunogênica, anticorpos, método de produção de um anticorpo, receptor de células t, polinucleotídeo, vetor, célula imune, célula t, peptídeo neoantigênico e população de células imunes | |
| CL2019003311A1 (es) | Nuevos péptidos (seq id no:82) y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer. (divisional solicitud 201800124) | |
| JP6914851B2 (ja) | 核酸ワクチン接種によるｃａｒ操作ｔ細胞の効果の増強 | |
| Arnold et al. | Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. | |
| Beatson et al. | MUC1 immunotherapy | |
| Oudard et al. | A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings | |
| UA124139C2 (uk) | Пептид, який здатний зв'язуватися з молекулою головного комплексу гістосумісності (мнс) людини і класу | |
| Salgaller et al. | Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides | |
| US11028181B2 (en) | Glycan-interacting compounds and methods of use | |
| MX2020005765A (es) | Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado. | |
| Van den Eynde et al. | New tumor antigens recognized by T cells | |
| US20240009306A1 (en) | Glycan-Interacting Compounds and Methods of Use | |
| CL2020002387A1 (es) | Péptidos (seq id no: 39) y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer (divisional de la solicitud no. 202002123) | |
| CL2020000817A1 (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer (divisional solicitud 201902093) | |
| BR112022001923A2 (pt) | Proteína de ligação ao antígeno, ácido nucleico isolado, célula hospedeira recombinante, composição farmacêutica, método de produção da proteína de ligação ao antígeno | |
| BR112018012826A2 (pt) | método para gerar linfócitos, para gerar um tcr e tcr específico para gage-1 | |
| PE20210517A1 (es) | Anticuerpos anti-hla-g y utilizacion de los mismos | |
| CL2019003421A1 (es) | Nuevos péptidos (seq id n°236), combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer. (divisional solicitud 201800545) | |
| TWI425952B (zh) | 具有抗原呈現細胞結合區及半胱胺酸富含區之免疫蛋白載體 | |
| CL2022002208A1 (es) | Receptor de células t restringido por hla de la clase i contra ras con mutación | |
| Willimsky et al. | In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo | |
| Sum et al. | The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation | |
| CL2019003326A1 (es) | Nuevos epítopos celulares y nuevas combinaciones de epítopos celulares para el uso de la inmunoterapia del mieloma y de otros tipos de cáncer. (divisional solicitud 201703244) | |
| JP2015163067A (ja) | 共有ｈｌａ−ｂ＊０７０２エピトープの同定、最適化および免疫療法のための使用 | |
| Rodeberg et al. | Lack of effective T-lymphocyte response to the PAX3/FKHR translocation area in alveolar rhabdomyosarcoma |